Come up with a name for your new list and we'll add to it:
Glyscend raised a round of funding on November 17, 2016. Investors include
Johnson & Johnson Innovation.
Glyscend is developing an approach to treating type 2 diabetes by recreating the effects of bariatric surgery, like gastric bypass, for diabetes and obesity without the need for invasive procedures.…